Brian joined Bionic Vision Technologies from Cochlear Ltd where he has held various senior engineering roles including most recently the position of Senior Portfolio Manager, Implants. Brian was responsible for delivery of Cochlear’s new implant projects to market. As CSO, Brian will oversee BVT’s future product development, clinical trials and regulatory approval initiatives required for the commercialisation of BVT’s retinal implant. From his time at Cochlear and RØDE, Brian brings his strong leadership and deep experience in program management and the full development and commercialization cycle of implantable devices. To date, BVT’s “bionic eye” has been implanted in 7 patients including 4 currently enrolled in the first trial of a completely portable device.
Bionic Vision Technologies Pty Ltd (BVT) is an Australian medical device company that aims to preserve and restore a sense of vision by developing a range of best in class technologies to address degenerative retinal conditions. BVT is commercialising the technologies developed by Bionic Vision Australia (BVA), a consortium of leading universities and research institutes funded by the Australian Research Council from 2010 to 31 December 2016. In April 2017, BVT received A$23.6 million from Hong Kong-based State Path Capital and China Huarong International Holdings. The funds enabled BVT to accelerate development and clinical studies. Consortium members collaborating on the trial include the Bionics Institute, Centre for Eye Research Australia, CSIRO’s Data 61, the University of Melbourne, and The Royal Victorian Eye and Ear Hospital. BVT will seek further capital to complete regulatory trials and technology development.